KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Levi Strauss (LEVI) Asset Writedowns and Impairment: 2010-2025

Historic Asset Writedowns and Impairment for Levi Strauss (LEVI) over the last 7 years, with Jun 2025 value amounting to $7.2 million.

  • Levi Strauss' Asset Writedowns and Impairment was N/A to $7.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $126.6 million, marking a year-over-year change of. This contributed to the annual value of $116.9 million for FY2024, which is 29.60% up from last year.
  • According to the latest figures from Q2 2025, Levi Strauss' Asset Writedowns and Impairment is $7.2 million, which was up 188.00% from $2.5 million recorded in Q1 2025.
  • In the past 5 years, Levi Strauss' Asset Writedowns and Impairment ranged from a high of $111.4 million in Q3 2024 and a low of -$12.8 million during Q4 2021.
  • Over the past 3 years, Levi Strauss' median Asset Writedowns and Impairment value was $7.2 million (recorded in 2025), while the average stood at $33.1 million.
  • Data for Levi Strauss' Asset Writedowns and Impairment shows a peak YoY increase of 4,174.07% (in 2021) and a maximum YoY decrease of 312.98% (in 2021) over the last 5 years.
  • Levi Strauss' Asset Writedowns and Impairment (Quarterly) stood at -$12.8 million in 2021, then reached $60.4 million in 2022, then plummeted by 106.13% to $90.2 million in 2023, then rose by 23.50% to $111.4 million in 2024, then plummeted by 54.55% to $7.2 million in 2025.
  • Its Asset Writedowns and Impairment was $7.2 million in Q2 2025, compared to $2.5 million in Q1 2025 and $111.4 million in Q3 2024.